Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study39
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics34
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies29
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)28
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d26
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function21
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation20
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens19
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential18
Editorial Board18
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients18
Editorial Board16
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma14
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets14
0.21869111061096